Neurogene Finalizes $134.8M Public Offering at $30/Share, Extends Cash Runway

summarizeSummary

Neurogene Inc. has finalized a public offering of common stock and pre-funded warrants, raising approximately $134.8 million at $30 per share, which will extend its cash runway into Q1 2029.

check_boxKey Events · Financing and Capital Events · NGNE

• Public Offering Finalized

  Neurogene entered into an underwriting agreement on June 30, 2026, to sell 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 per warrant.

• Underwriters' Option Exercised

  The underwriters fully exercised their option on July 1, 2026, to purchase an additional 624,999 shares of common stock.

• Significant Capital Raised

  The offering is expected to generate approximately $134.8 million in net proceeds, after deducting underwriting discounts and estimated expenses.

• Extended Cash Runway

  The company anticipates these proceeds, combined with existing cash, will fund its operating expenses and capital expenditure requirements into the first quarter of 2029, extending its previous runway by one year.

auto_awesomeAnalysis · NGNE · Life Sciences

This 8-K formalizes the terms and closing of Neurogene's significant public offering, which was previously announced and priced. The company will raise approximately $134.8 million, which is a substantial capital infusion representing about 25% of its current market capitalization. While dilutive, this capital raise is critical for a life sciences company, extending its cash runway by a year, from Q1 2028 to Q1 2029, and funding the development of its gene therapies, especially following recent positive clinical data for NGN-401.